Mitsubishi UFJ Trust & Banking Corp Has $81.41 Million Stake in Moderna, Inc. (NASDAQ:MRNA)

Mitsubishi UFJ Trust & Banking Corp reduced its stake in Moderna, Inc. (NASDAQ:MRNA) by 9.4% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 763,976 shares of the company’s stock after selling 79,656 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.20% of Moderna worth $81,408,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Ogorek Anthony Joseph NY ADV bought a new position in shares of Moderna in the fourth quarter worth about $27,000. Arlington Trust Co LLC increased its position in Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after buying an additional 290 shares during the period. Westside Investment Management Inc. bought a new stake in shares of Moderna in the first quarter valued at approximately $32,000. Rise Advisors LLC boosted its position in shares of Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after acquiring an additional 286 shares during the period. Finally, UMB Bank n.a. grew its stake in shares of Moderna by 121.8% in the first quarter. UMB Bank n.a. now owns 366 shares of the company’s stock worth $39,000 after acquiring an additional 201 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

NASDAQ MRNA traded down $0.18 during trading hours on Friday, reaching $121.14. 2,206,322 shares of the company’s stock were exchanged, compared to its average volume of 3,370,375. The firm has a fifty day moving average of $135.45 and a 200-day moving average of $114.69. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a one year low of $62.55 and a one year high of $170.47. The stock has a market cap of $46.43 billion, a PE ratio of -7.73 and a beta of 1.66.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping the consensus estimate of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. During the same quarter in the prior year, the business earned $0.19 earnings per share. The business’s revenue for the quarter was down 91.0% on a year-over-year basis. On average, equities research analysts predict that Moderna, Inc. will post -7.46 earnings per share for the current fiscal year.

Insider Transactions at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $108.32, for a total value of $1,624,800.00. Following the completion of the transaction, the director now owns 2,041,931 shares in the company, valued at approximately $221,181,965.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, President Stephen Hoge sold 255 shares of the firm’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $120.96, for a total value of $30,844.80. Following the transaction, the president now owns 1,486,508 shares of the company’s stock, valued at approximately $179,808,007.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $108.32, for a total transaction of $1,624,800.00. Following the sale, the director now directly owns 2,041,931 shares of the company’s stock, valued at $221,181,965.92. The disclosure for this sale can be found here. Over the last three months, insiders have sold 396,239 shares of company stock worth $55,286,137. Corporate insiders own 15.70% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on MRNA shares. Royal Bank of Canada increased their price target on shares of Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a report on Monday, June 3rd. UBS Group lifted their target price on Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Piper Sandler reaffirmed an “overweight” rating and issued a $214.00 price target on shares of Moderna in a report on Thursday, June 27th. Oppenheimer lifted their price objective on Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a report on Wednesday, June 12th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Moderna presently has an average rating of “Hold” and an average target price of $134.02.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.